Jubilant Therapeutics

Jubilant Therapeutics Inc. is a biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases. The company is committed to developing effective and selective small molecule modulators to tackle unmet medical needs in oncology and autoimmune diseases. Its advanced discovery engine integrates structure-based design and computational algorithms to discover and develop novel precision therapies targeting first-in-class and validated but difficult-to-drug targets in genetically defined patient populations. The company is advancing its lead program – a first-in-class dual inhibitor of LSD1/HDAC6 – into Phase 1/2a, followed by additional INDs for novel brain-penetrant modulators targeting PRMT5 and PDL1, as well as a PAD4 inhibitor for oncology and inflammatory indications.